Estrella Immunopharma Files 8-K
Ticker: ESLAW · Form: 8-K · Filed: Jun 5, 2025 · CIK: 1844417
Sentiment: neutral
Topics: 8-K, corporate-events, financial-reporting
TL;DR
Estrella Immunopharma filed an 8-K on June 5, 2025. Nothing major, just standard reporting.
AI Summary
Estrella Immunopharma, Inc. filed an 8-K on June 5, 2025, reporting other events and financial statements. The company, formerly known as TradeUP Acquisition Corp. until February 4, 2021, is based in Emeryville, California, and operates in the biological products sector.
Why It Matters
This filing provides an update on Estrella Immunopharma's corporate events and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for other events and financial statements, not indicating any immediate significant risks or changes.
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- TradeUP Acquisition Corp. (company) — Former Company Name
- June 5, 2025 (date) — Date of Report
- Emeryville, California (location) — Company Address
FAQ
What is the primary purpose of this 8-K filing for Estrella Immunopharma, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of June 5, 2025.
When did Estrella Immunopharma, Inc. change its name from TradeUP Acquisition Corp.?
Estrella Immunopharma, Inc. changed its name from TradeUP Acquisition Corp. on February 4, 2021.
What is Estrella Immunopharma, Inc.'s Standard Industrial Classification (SIC) code?
Estrella Immunopharma, Inc.'s SIC code is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Where is Estrella Immunopharma, Inc. located?
Estrella Immunopharma, Inc. is located at 5858 Horton Street, Suite 370, Emeryville, California, 94608.
What is the SEC file number for Estrella Immunopharma, Inc.?
The SEC file number for Estrella Immunopharma, Inc. is 001-40608.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding Estrella Immunopharma, Inc. (ESLAW).